Upregulation of kallikrein‑related peptidase 5 is associated with the malignant behavior of colorectal cancer

Wu,Yanhua; Chen,Yingjian; Li,Qing; Gong,Yanwen; Liu,Xiaohong; Bi,Liquan; Hu,Chengjin

doi:10.3892/mmr.2016.5516

Upregulation of kallikrein‑related peptidase 5 is associated with the malignant behavior of colorectal cancer

Authors:
- Yanhua Wu
- Yingjian Chen
- Qing Li
- Yanwen Gong
- Xiaohong Liu
- Liquan Bi
- Chengjin Hu
View Affiliations

Affiliations: Department of Laboratory Medicine, General Hospital of Jinan Military Command, Jinan, Shandong 250031, P.R. China, Department of Clinical Laboratory, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277102, P.R. China, Department of Pathology, General Hospital of Jinan Military Command, Jinan, Shandong 250031, P.R. China
Published online on: July 13, 2016 https://doi.org/10.3892/mmr.2016.5516
Pages: 2164-2170

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Kallikrein-related peptidase 5 (KLK5) is a serine protease that has exhibited upregulated expression in numerous types of human cancer. The present study assessed KLK5 expression in colorectal cancer (CRC) tissues, in order to determine its association with clinicopathological data and prognosis. The mRNA and protein expression levels of KLK5 were detected using reverse transcription‑quantitative polymerase chain reaction, immunohistochemistry and enzyme‑linked immunosorbent assay, respectively. KLK5 expression was detected in 48 paraffin‑embedded tumor tissue samples and corresponding tumor‑free areas within the same specimens, 40 paired normal and CRC frozen tissues, and serum samples from 70 patients with CRC (including 38 serum samples taken pre‑ and post‑surgery) and 53 healthy individuals. The results demonstrated that KLK5 protein was strongly expressed in CRC; however, its expression was hardly detected in the matched normal mucosal tissue. The KLK5 mRNA expression levels were significantly upregulated in CRC tissues compared with the paired normal tissues, and were higher in Dukes' stage C/D cancer than in stage A/B (P<0.001). Furthermore, sera from patients with CRC exhibited increased KLK5 levels, as compared with that of healthy volunteers (878.02 vs. 391.07 pg/ml; P<0.001). Serum KLK5 levels were also significantly higher in patients prior to surgery compared with post‑surgery (909.48±536.72 vs. 644.00±522.87 pg/ml; P<0.001). In addition, increased serum KLK5 levels were associated with CRC lymph node or distant metastasis (P=0.003), tumor‑lymph node‑metastasis stage (P=0.004), and Dukes' stage (P=0.005). The results of the present study indicated that the mRNA and protein expression levels of KLK5 were significantly upregulated in CRC tissues and sera, and were associated with an advanced tumor stage. Further studies may identify KLK5 as a biomarker of CRC recurrence or treatment response.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	McCracken M, Olsen M, Chen MS Jr, Jemal A, Thun M, Cokkinides V, Deapen D and Ward E: Cancer incidence, mortality, and associated risk factors among asian americans of chinese, filipino, vietnamese, korean, and Japanese ethnicities. CA Cancer J Clin. 57:190–205. 2007. View Article : Google Scholar : PubMed/NCBI
3	Sarela AI: Systematic review of genetic influences on the prognosis of colorectal cancer (Br J Surg 2004; 91: 1275–1291). Brit J Surg. 91:1275–1291. 2004. View Article : Google Scholar
4	Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C and Topolcan O: Clinical utility of biochemical markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines. Eur J Cancer. 39:718–727. 2003. View Article : Google Scholar : PubMed/NCBI
5	Thomas SN, Tong Z, Stebe KJ and Konstantopoulos K: Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnostics. Biorheology. 46:207–225. 2009.
6	Hammarström S: The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 9:67–81. 1999. View Article : Google Scholar : PubMed/NCBI
7	Borgoño CA, Michael IP and Diamandis EP: Human tissue kallikreins: Physiologic roles and applications in cancer. Mol Cancer Res. 2:257–280. 2004.PubMed/NCBI
8	Yousef GM and Diamandis EP: The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation. J Biol Chem. 274:37511–37516. 1999. View Article : Google Scholar : PubMed/NCBI
9	Brattsand M and Egelrud T: Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J Biol Chem. 274:30033–30040. 1999. View Article : Google Scholar : PubMed/NCBI
10	Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G and Diamandis EP: Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J Biol Chem. 281:12743–12750. 2006. View Article : Google Scholar : PubMed/NCBI
11	Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G and Diamandis EP: Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem. 280:14628–14635. 2005. View Article : Google Scholar : PubMed/NCBI
12	Ohler A, Debela M, Wagner S, Magdolen V and Becker-Pauly C: Analyzing the protease web in skin: Meprin metalloproteases are activated specifically by KLK4, 5 and 8 vice versa leading to processing of proKLK7 thereby triggering its activation. Biol Chem. 391:455–460. 2010. View Article : Google Scholar : PubMed/NCBI
13	Diamandis EP and Yousef GM: Human tissue kallikreins: A family of new cancer biomarkers. Clin Chem. 48:1198–1205. 2002.PubMed/NCBI
14	Kim H, Scorilas A, Katsaros D, Yousef GM, Massobrio M, Fracchioli S, Piccinno R, Gordini G and Diamandis EP: Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer. 84:643–650. 2001. View Article : Google Scholar : PubMed/NCBI
15	Yousef GM, Scorilas A, Kyriakopoulou LG, Rendl L, Diamandis M, Ponzone R, Biglia N, Giai M, Roagna R, Sismondi P and Diamandis EP: Human kallikrein gene 5 (KLK5) expression by quantitative PCR: An independent indicator of poor prognosis in breast cancer. Clin Chem. 48:1241–1250. 2002.PubMed/NCBI
16	Avgeris M, Papachristopoulou G, Polychronis A and Scorilas A: Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: A biomarker for the differential diagnosis of breast lesions. Clin Proteomics. 8:52011. View Article : Google Scholar : PubMed/NCBI
17	Yousef GM, Obiezu CV, Jung K, Stephan C, Scorilas A and Diamandis EP: Differetial expression of kallikrein gene 5 in cancerous and normal testicular tissues. Urology. 60:714–718. 2002. View Article : Google Scholar : PubMed/NCBI
18	Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, Scorilas A, Borgoño C, Harbeck N, Schmalfeldt B, Dorn J, et al: Human kallikrein 5: A potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 63:3958–3965. 2003.PubMed/NCBI
19	Korbakis D, Gregorakis AK and Scorilas A: Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: An independent cancer biomarker. Clin Chem. 55:904–913. 2009. View Article : Google Scholar : PubMed/NCBI
20	Sotiropoulou G, Pampalakis G and Diamandis EP: Functional roles of human kallikrein-related peptidases. J Biol Chem. 284:32989–32994. 2009. View Article : Google Scholar : PubMed/NCBI
21	Talieri M, Li L, Zheng Y, Alexopoulou DK, Soosaipillai A, Scorilas A, Xynopoulos D and Diamandis EP: The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer. 100:1659–1665. 2009. View Article : Google Scholar : PubMed/NCBI
22	Wu Y, Liu X, Chen Y and Hu C: Development and evaluation of an ELISA method for the measurement of kallikrein-related peptidase 5 (KLK5) in human serum. Open J Clin Diagn. 3:159–166. 2013. View Article : Google Scholar
23	Fan X, Liu B, Xu H, Yu B, Shi S, Zhang J, Wang X, Wang J, Lu Z, Ma H and Zhou X: Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples. Human Pathology. 44:1499–1507. 2013. View Article : Google Scholar : PubMed/NCBI
24	Anthony T, Simmang C, Hyman N, Buie D, Kim D, Cataldo P, Orsay C, Church J, Otchy D, Cohen J, et al Standards Practice Task Force, The American Society of Colon and Rectal Surgeons: Practice parameters for the surveillance and follow-up of patients with colon and rectal cancer. Dis Colon Rectum. 47:807–817. 2004. View Article : Google Scholar : PubMed/NCBI
25	Avgeris M, Mavridis K and Scorilas A: Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem. 391:505–511. 2010. View Article : Google Scholar : PubMed/NCBI
26	Mavridis K and Scorilas A: Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol. 6:269–285. 2010. View Article : Google Scholar : PubMed/NCBI
27	Diamandis EP, Borgoño CA, Scorilas A, Yousef GM, Harbeck N, Dorn J, Schmalfeldt B and Schmitt M: Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumour Biol. 24:299–309. 2003. View Article : Google Scholar
28	Kurlender L, Yousef GM, Memari N, Robb JD, Michael IP, Borgoño C, Katsaros D, Stephan C, Jung K and Diamandis EP: Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer. Tumor Biol. 25:149–156. 2004. View Article : Google Scholar
29	Kim JT, Song EY, Chung KS, Kang MA, Kim JW, Kim SJ, Yeom YI, Kim JH, Kim KH and Lee HG: Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer. Cancer. 117:2608–2619. 2011. View Article : Google Scholar : PubMed/NCBI
30	Talieri M, Alexopoulou DK, Scorilas A, Kypraios D, Arnogiannaki N, Devetzi M, Patsavela M and Xynopoulos D: Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumor Biol. 32:737–744. 2011. View Article : Google Scholar
31	White NM, Bui A, Mejia-Guerrero S, Chao J, Soosaipillai A, Youssef Y, Mankaruos M, Honey RJ, Stewart R, Pace KT, et al: Dysregulation of kallikrein-related peptidases in renal cell carcinoma: Potential targets of miRNAs. Biol Chem. 391:411–423. 2010. View Article : Google Scholar : PubMed/NCBI
32	White NM, Chow TF, Mejia-Guerrero S, Diamandis M, Rofael Y, Faragalla H, Mankaruous M, Gabril M, Girgis A and Yousef GM: Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer. 102:1244–1253. 2010. View Article : Google Scholar : PubMed/NCBI